Molecules have long been the primary asset in life sciences. Companies develop therapeutics, protect them with patents, and license or sell them. With the rise of artificial intelligence (AI), the data generated in the course of researching and developing molecules has become an asset in its own right.
A market has formed around that shift. AI-native biotech companies have spent years generating the proprietary data needed to train AI models — through clinical genomics and patient sample networks, automated wet labs, and spatial biology platforms — and building the integrated platforms to do it. They now license those models as products and services to life sciences companies that are sitting on decades of their own accumulated research, which AI can analyze to identify drug candidates, predict treatment response, and map disease biology.